News 16.05.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...
News 15.05.2025 According to a press release, the Schlieren-based biotech company Biognosys has fully equipped the first laboratory in Europe with its P2 plasma enrichment system. The system has been installed at the Proteomics Core Facility at the University of Gothenburg. This is an important step in making Biognosys' P2 technology more...
News 13.05.2025 CUTISS has completed patient recruitment in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns. This randomized, controlled trial compares denovoSkin™ to the current standard of care, autografting, using an intra-patient control design. It is one of three Phase 2 trials designed to...
News 13.05.2025 Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be...
News 08.05.2025 Lightium won the Prix Strategis 2025. The startup develops photonic chips for telecommunications and artificial intelligence. The Strategis Prize is awarded by HEC Espace Entreprise in Lausanne. Lightium, a start-up that specializes in photonic integrated circuits, won the Prix Strategis for the 32nd time this year. Based in the Bio-Technopark Schlieren-Zurich,...